A Practical Guide to the Safety and Monitoring of New IBD Therapies

Click B1, Regueiro M1. Inflamm Bowel Dis. 2018 Oct 12. doi: 10.1093/ibd/izy313. [Epub ahead of print]

Author information

1 Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, USA.


The therapeutic armamentarium of inflammatory bowel disease is rapidly evolving with the development of novel treatment options including targeted monoclonal antibodies and small molecules. With these new therapies come additional safety and side effect concerns. Infections, malignancies, immunogenicity, and metabolic issues exist for each treatment. Management of these agents in the face of such complications is a challenge clinicians will encounter. In this article, we review the existing safety data behind the monoclonal antibodies and small molecules, suggest appropriate risk stratification and assessment considerations before and during therapy, and make expert recommendations on the management of potential complications or clinical scenarios.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.